Please login to the form below

Not currently logged in
Email:
Password:

Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head

Moves to the Boston company from Onyx Pharmaceuticals
Intarcia Therapeutics Sunita Zalani

Boston-based biopharmaceutical firm Intarcia Therapeutics has appointed Dr Sunita Zalani as vice president, global head of regulatory affairs and quality.

She joins the company from Amgen's Onyx Pharmaceuticals subsiary, where she served as vice president of global regulatory affairs.

Dr Zalani had been with Onyx - which was acquired by Amgen last year - since 2004 and prior to that worked at Lilly as its global regulatory lead.

In her new role at Inarcia, whose most advanced prospect is a phase III version of the diabetes drug exenatide that only needs to be given once a year, Dr Zalani will sit on the leadership team and report directly to chairman, president and CEO Kurt Graves.

He said: "We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had.

“Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry.”

6th August 2014

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics